PYC Therapeutics Limited (AU:PYC) has released an update.
PYC Therapeutics Limited has made significant strides in Q1 2024, advancing three innovative drug candidates targeting severe diseases with no current treatments, including two blinding eye conditions and a form of kidney disease. The company successfully completed early-stage trials for their Retinitis Pigmentosa drug and is preparing for human trials for their kidney and eye disease treatments, with clinical proof of concept data expected in 2025. Following a successful $74.6 million funding round, PYC is well-positioned financially, with a cash runway of over $100 million to support upcoming safety and efficacy trials.
For further insights into AU:PYC stock, check out TipRanks’ Stock Analysis page.
